A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer
Loomer, H.P.; Saunders, J.C.; Kline, N.S.
Psychiatric Research Reports 8: 129-141
1957
ISSN/ISBN: 0555-5434 PMID: 13542681 Document Number: 8105
An original survey has been presented of the psychiatric effects of iproniazid, evaluating its clinical and pharmacodynamic properties as a psychic energizer. And our preliminary findings, after more than 5 months of study, are herewith summarized: 1. Our preliminary clinical experience with iproniazid leads us to believe that it is effective in depressed, deteriorated, and regressed patients. 2. The over-all response to this drug proved favorable in 70 per cent of the 17 hospital cases studied, with varying degrees of improved general attitude and behavior, better ward adjustment, increased weight, heightened affective mood, and added interest in self and environment. 3. The dosage must be individualized in order to obtain maximum therapeutic response and minimum side effects. However, we have found an oral dose of 50 mg. t.i.d. to be highly effective. 4. Iproniazid must be used with caution, since it may produce neurological and/or psychological changes if administered in high dosages for a long term. 5. The preliminary results warrant continued clinical trials in the type of patients we have discussed, as well as in other psychiatric disorders of a related nature. 6. Our results with combination therapy have not been evaluated at this time, but will be reported in the near future. 7. Whatever the mechanism of iproniazid may be, it would appear as though with it a new pharmacological approach is now available for adjunctive therapy in psychiatry.
Document emailed within 1 workday
